Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Employees - 10, CEO - Dr. Neil Maresky M.D., Sector - Healthcare, Country - CA, Market Cap - 3.11M

Altman ZScore(max is 10): -33.41, Piotroski Score(max is 10): 3, Working Capital: $-1265232, Total Assets: $2253498, Retained Earnings: $-54498339, EBIT: -1556173, Total Liabilities: $3508604, Revenue: $0

AryaFin Target Price - $-1.08 - Current Price $5.32 - Analyst Target Price $-